
MECLIZINE HYDROCHLORIDE- meclizine hydrocloride tablet Proficient Rx LP

MECLIZINE HYDROCHLORIDE TABLETS, USP Rx only

DESCRIPTION

Chemically, Meclizine HCl is $1-(p-chloro-\alpha-phenylbenzyl)-4-(m-methylbenzyl)$ piperazine dihydrochloride monohydrate.



 $C_{25}H_{27}ClN_2$. 2HCl. H_2O

481.88

Meclizine HCI Tablets, USP are available in two different strengths: 12.5 mg and 25 mg. In addition each tablet contains the following inactive ingredients: Colloidal Silicon Dioxide, Croscarmellose Sodium, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose. Also, Meclizine HCI Tablets USP, 12.5 mg contains FD&C Blue #1 Aluminum Lake (11-13%) and Meclizine HCI Tablets USP, 25 mg contains D&C Yellow #10 Aluminum Lake (15-20%).

M.W.

CLINICAL PHARMACOLOGY

Meclizine Hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

INDICATIONS AND USAGE

For the management of nausea and vomiting, and dizziness associated with motion sickness.

CONTRAINDICATIONS

Meclizine Hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

WARNINGS

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

Patients should avoid alcoholic beverages while taking this drug.

Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.

PRECAUTIONS

PREGNANCY, Teratogenic Effects

Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that medicine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.

Pediatric Use

Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.

ADVERSE REACTIONS

Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.

DOSAGE AND ADMINISTRATION

Motion Sickness

The initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

HOW SUPPLIED

Meclizine HCI Tablets, USP are available in the following strengths and package sizes:

25 mg (Yellow, oval-shaped, scored, debossed with TL121)

Bottles of 10 NDC 63187-996-10

Bottles of 20 NDC 63187-996-20

Bottles of 30 NDC 63187-996-30

Store at 20-25°C (68-77°F) (See USP Controlled Room Temperature].

Manufactured By:

Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA. Repackaged by: Proficient Rx LP Thousand Oaks CA.91320 Revised 03/11

PRINCIPAL DISPLAY PANEL



#10



Each tablet contains: 25 mg of meclizine HCI. (Yellow, oval shaped tablets, debossed with "TL 121" with score on one side

Mfr. By: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA

NDC 63187-996-10

Packaged By: Proficient Rx LP Thousand Oaks, CA 91320

RX Only

Keep medication out of the reach of children

Meclizine HCI 25mg #10 Tablets Lot #:00000 NDC 63187-996-10

SN# MASTER Exp:00/00/00

Meclizine HCI 25mg #10 Tablets Lot #:00000 NDC 63187-996-10

SN# MASTER Exp:00/00/00

Meclizine HCI 25mg #10 Tablets Lot #00000 NDC 63187-996-10

SN#MASTER Exp:00/00/00



GTIN: 00363187996109 SN# MASTER Exp. 00/00/00 Lot #:00000

NDC 63187-996-10

and plain on the other side.)

Store at 20°-25°C (68°-77°F)

Product ID: PM099610

Meclizine Hydrochloride Tablets, USP

Meclizine HCI 25mg

Tablets

25 mg

10 Tablets

Rx Only

Each tablet Contains 25 mg of meclizine HCl

DOSAGE AND USE See accompanying prescribing information

MOTION SICKNESS:

25 mg to 50 mg daily.

Dispense in tight, light-resistant containers (USP).

Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature].

MECLIZINE HYDROCHLORIDE

meclizine hydrocloride tablet

Product Information

Product Type

HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:63187-996(NDC:59746-121)

Route of Administration		ORAL											
Active Ingredient/Active Moiety													
			Ingredie	nt Name			Basis of Stren			gth	Strength		
Meclizine Hydrochloride (UNII: HDP7W44CIO) (Meclizine - UNII:3L5TQ84570) Meclizine Hydrochloride (UNII: HDP7W44CIO) (Meclizine - UNII:3L5TQ84570)								Meclizine Hydro	ochloride 25 mg		25 mg		
Inactive Ingredients													
Ingredient Name										Strength			
Silicon Dioxide (UNII: ETJ7Z6XBU4)													
Croscarmellose Sodium (UNII: M28OL1HH48)													
	Lactose Monohydrate (UNII: EWQ57Q8I5X)												
Magnesium Stearate (UNII: 70097M6I30)													
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)													
D&c Yellow No. 10 (UNII: 35SW5USQ3G)													
Aluminum Oxide (UNII: LMI26O6933)													
Product Characteristics													
Color			YELLOW Score				2 n			pieces			
Shape			OVAL	Size					3mm				
Flavor			0,112	Imprint Code						Ľ121			
Contains							1.51						
Contains													
Packagi	ng												
	1 Code		Packa	age Descripti	on		Marketin	g Start Date	Ma	rketin	g End Date		
1 NDC:631	87-996-10	10 in 1	BOTTLE; Type 0: Not a Combination Produc			duct	05/12/2020	0			0		
2 NDC:631	87-996-20	20 in 1	1 BOTTLE; Type 0: Not a Combination Produc			duct	0 3/0 1/20 18						
3 NDC:631	B NDC:63187-996-30 30 in 1 B			BOTTLE; Type 0: Not a Combination Product			0 1/0 1/20 19						
Marketing Information													
	•		plication Number or Monograph Citation				Marketing Start Date M			Marketing End Date			
		A040659				06/04/2010			S LINE Date				
			10 10 000				00,04/201						

Labeler - Proficient Rx LP (079196022)

Establishment											
Name	Address	ID/FEI	Business Operations								
Proficient Rx LP		079196022	REPACK(63187-996), RELABEL(63187-996)								